Blackstone Group Inc. is extending its big bet on biotechnology and other life-science buildings, a hot field in the real-estate world that is heating up even more as scientists pursue a vaccine for Covid-19. The New York investment firm said it looked at selling or taking public BioMed Realty Trust, the second-largest U.S. owner of life-science buildings with 93 properties, which Blackstone acquired in 2016. The Blackstone fund that owns the company eventually needs to exit all holdings and return money to investors.

Source: Wall Street Journal October 15, 2020 21:22 UTC